NEMAURA MEDICAL, INC. (OTCMKTS:NMRD) Files An 8-K Other Events
Item 8.01. Other Events
On May 29, 2019, Nemaura Medical Inc. issued a press release announcing CE Mark approval of SugarBEAT®, as the world’s first non-invasive continuous glucose monitor. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description |
| 99.1 | Press Release, dated May 29, 2019 |
Nemaura Medical Inc. Exhibit
EX-99.1 2 nmra_ex99x1.htm EXHIBIT 99.1 Exhibit 99.1 Nemaura Announces CE Mark Approval of SugarBEAT® SugarBEAT® is the World’s First Non-Invasive Continuous Glucose Monitor Loughborough,…
To view the full exhibit click here
About NEMAURA MEDICAL, INC. (OTCMKTS:NMRD)
Nemaura Medical, Inc. is a holding company. The Company owns a diagnostic medical device company specializing in discovering, developing and commercializing specialty medical devices. The Company’s focus is on the development of a continuous glucose monitoring (CGM) device, which consists of a disposable patch containing a sensor, and a non-disposable miniature electronic watch with a re-chargeable power source. CGM through a non-invasive patch can enable early detection of subtle changes in blood glucose levels. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a CGM, named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes, and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm.
